KainosMed Hires Consultant for Technology Transfer to US Subsidiary

Hiring Dr. David Song with Expertise in Finance, Investment, and Analysis
Forming a Dream Team to Maximize Technology Value

[Asia Economy Reporter Kwangho Lee] Kainosmed (284620), a new drug company for brain disease treatment, announced on the 29th that its U.S. subsidiary Fascinate Therapeutics, Inc. has recruited Dr. David Song, who holds a medical degree and expertise in global finance, investment, and analysis, as a consultant. This recruitment was made to successfully conclude ongoing technology transfers and investment attraction discussions.

David Song is a Korean-American who graduated from Yale University with a degree in Molecular Biology and Biochemistry, earned a medical degree from the Perelman School of Medicine at the University of Pennsylvania, one of the top medical schools in the U.S., and obtained a Ph.D. in Economics from the Wharton School of Business. He is a medical and biotechnology finance expert.

In the finance sector, he discovered and directly managed investments and asset management for pharmaceutical, medical, and biotechnology companies at Rockefeller Capital Management in New York and Millennium Partners asset management firm. At UBS Securities, where he was responsible for global asset management and investment banking, he worked as a senior analyst in the biomedical field.

He led roles as a professional analyst in the medical and biotechnology fields, including market analysis and commercialization strategies. In investment asset management, he generated excellent investment returns for public and private healthcare companies over 15 years, provided consulting in corporate strategy, environmental, social, and governance (ESG), and biotechnology?especially in the healthcare sector?and formed networks with institutional investors and over 200 healthcare-related entities.

Kainosmed is conducting Phase 2 clinical trials in the U.S. for Parkinson’s disease treatment with ‘KM-819,’ a FAF1 inhibitor, and Phase 2 clinical trials in Korea for multiple system atrophy treatment. If successful, it will develop the world’s first Parkinson’s disease treatment.

A Kainosmed official said, “At a time when the Phase 2 clinical trial for the Parkinson’s disease treatment is progressing smoothly, we are forming a dream team to successfully conclude investment attraction for our subsidiary and maximize the value of technology through partnering or licensing out. The first step was to bring Dr. David Song, who holds medical and economics doctorates and is a finance expert in the bio field, as a consultant.”

This content was produced with the assistance of AI translation services.